- Purple Biotech ( NASDAQ: PPBT ) stock rose ~6% on Tuesday after the company said it entered a research collaboration with Mor Research Applications.
- The agreement provides Purple first access to early-stage oncology product candidates owned by Mor, the company added.
- Under the agreement, Purple will have the option to fund early development aiming both to in-license selected drug assets and to pursue their development and commercialization, according to the company.
- Mor is a technology transfer unit of Clalit Healthcare Services, a Health Maintenance Organization (HMO) in Israel serving ~4.8M members and operating 14 hospitals, Purple noted.
- "This research collaboration with Mor will provide us access to numerous early-stage assets that have been developed by leading researchers and scientists in Israel," said Purple CEO Gil Efron.
For further details see:
Purple Biotech stock rises on team up with Mor for research on cancer drugs